Business UpdateJul 9, 2026, 04:02 PM
20/20 BioLabs Outlines OneTest™ Strategy for Medicare Reimbursement
AI Summary
20/20 BioLabs outlined its strategy to position OneTest™ for Cancer as an affordable, multi-cancer early detection blood test, aiming for potential Medicare reimbursement under a new statutory pathway beginning in 2028. The company highlighted its differentiated approach using protein tumor markers and serial testing, and provided preliminary estimates for its second-quarter MCED revenue, expecting it to be its highest to date and at least 30% higher than the prior-year period. However, the company emphasized that FDA authorization and CMS determination of clinical appropriateness are required and not yet obtained.
Key Highlights
- Q2 MCED revenue expected to be highest to date.
- Q2 MCED revenue projected at least 30% higher than prior-year Q2.
- Medicare reimbursement pathway for FDA-authorized MCED tests begins 2028.
- OneTest™ uses protein tumor markers, inflammation biomarkers, ML, serial testing.
- Over 35,000 firefighters expected to be tested by end of 2026.
- OneTest™ for Longevity platform integrates inflammatory biomarkers.
Price Impact
More from AIDX